Renal Cell Carcinoma
Conditions
Brief summary
The present study will aim to describe and understand, in the real-world, the clinical characteristics, treatment patterns and outcomes of advanced renal cell carcinoma (aRCC) patients treated with cabozantinib or axitinib monotherapy in England using the existing data source, Cancer Analysis System (CAS).
Interventions
DRUGCabozantinib
oral therapy
DRUGAxitinib
oral therapy
Sponsors
Ipsen
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with initial renal cancer diagnosis * Patients diagnosed at Stage III or Stage IV (as defined in CAS): as evidence for advanced/metastatic RCC * For patients with Stage I/II or patients with missing information on Staging * Patients who received SACT1 treatment following initial renal cancer diagnosis through end of enrolment (31 July 2019) * Patients who received cabozantinib or axitinib treatment
Exclusion criteria
* Diagnosis of concomitant tumour apart from non-melanoma skin cancer in the three years prior to the diagnosis of aRCC * Less than 18 years of age at the time of initial aRCC diagnosis * SACT treatment more than 30 days prior to initial aRCC diagnosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Duration of therapy for the index treatments of interest stratified by line of therapy (LoT) | From start of index treatment up to the end of treatment or start of subsequent therapy during data collection period (01 January 2011 and 31 January 2020) | Duration of therapy will be measured from the initiation of the index treatment until the projected end date of the index treatment (or start of the subsequent therapy). (subgroups 1 to 4) |
| Time between subsequent treatment lines | From baseline until the end of data collection period (01 January 2011 and 31 January 2020) | Time gap between the projected end date of the index treatment (cabozantinib or axitinib) until the start of the subsequent treatment. (subgroups 1 to 4) |
| Sequencing of treatments (any treatments received from aRCC diagnosis until the end of follow up or death) | From baseline until the end of data collection period (01 January 2011 and 31 January 2020) | Treatment sequencing will be presented using a Sankey diagram that visualises the regimens received within each line of therapy and the number and percentage of patients who received those particular regimens. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time from RCC diagnosis to treatment initiation of axitinib | From baseline until the end of data collection period (01 January 2011 and 31 January 2020) | Time from diagnosis of RCC until the start of the prescription of axitinib. |
| Time from aRCC diagnosis to treatment initiation of cabozantinib | From baseline until the end of data collection period (01 January 2011 and 31 January 2020) | Time from diagnosis of aRCC until the start of the first prescription of cabozantinib. (subgroups 1 and 3) |
| Time from aRCC diagnosis to treatment initiation of axitinib | From baseline until the end of data collection period (01 January 2011 and 31 January 2020) | Time from diagnosis of aRCC until the start of the first prescription of axitinib. (subgroups 2 and 4) |
| Time from aRCC diagnosis to initial SACT initiation | From baseline until the end of data collection period (01 January 2011 and 31 January 2020) | Defined as the time from diagnosis of aRCC until the start date of the first cycle of the SACT regimen (i.e., 1st LoT start). (subgroups 1 to 4) |
| Landmark survival | 12 months | Landmark survival will be defined as the time from start of the index treatment until date of death (from any cause) at specific time points (12, 18, and 24 months). (subgroups 1 to 4) |
| Time to next treatment (or death) (TTNT) | From start of index treatment until the start of subsequent therapy during data collection period (01 January 2011 and 31 January 2020) | Time to next treatment (or death) (TTNT) will be defined as the time from start of index treatment until the start of the subsequent LoT (subgroups 1 to 4) |
| Time to treatment discontinuation (TTTD) | From start of index treatment until discontinuation or death during data collection period (01 January 2011 and 31 January 2020) | Time to treatment discontinuation (TTTD) will be defined as time from treatment initiation until treatment discontinuation or death. (subgroups 1 to 4) |
| Overall survival (OS) | From start of index treatment until death or end of data collection period (01 January 2011 and 31 January 2020 whichever occurs first | Time from start of index treatment (cabozantinib/axitinib) until the date of death (from any cause) during the study period. (subgroups 1 to 4) |
| Time from RCC diagnosis to initial SACT initiation | From baseline until the end of data collection period (01 January 2011 and 31 January 2020) | Time from RCC diagnosis to initial SACT initiation will be defined as the time from diagnosis of RCC until the start date of the first cycle of the SACT regimen. (subgroups 1 to 4) |
| Time from RCC diagnosis to treatment initiation of cabozantinib | From baseline until the end of data collection period (01 January 2011 and 31 January 2020) | Time from diagnosis of RCC until the start of the first prescription of cabozantinib. (subgroups 1 and 3) |
Countries
United Kingdom
Outcome results
None listed